https://www.aurigene.com/publications/ 2026-04-22T03:15:44+00:00 https://www.aurigene.com/publications/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-aur101-an-ror%ce%b3t-inhibitor-in-normal-healthy-volunteers/ 2022-11-15T04:43:36+00:00 https://www.aurigene.com/publications/discovery-and-clinical-development-of-the-first-small-molecule-checkpoint-inhibitor-for-cancer-therapy/ 2022-11-15T05:57:13+00:00 https://www.aurigene.com/publications/phase-2-trial-of-ca-170-a-novel-oral-small-molecule-dual-inhibitor-of-immune-checkpoints-vista-and-pd-1-in-patients-pts-with-advanced-solid-tumor-and-hodgkin/ 2022-11-15T05:59:03+00:00 https://www.aurigene.com/publications/phase-2-trial-of-ca-170-a-novel-oral-small-molecule-dual-inhibitor-of-immune-checkpoints-vista-and-pd-1-in-patients-pts-with-advanced-solid-tumor-and-hodgkin-2/ 2022-11-15T05:59:26+00:00 https://www.aurigene.com/publications/pd-1-derived-ca-170-is-an-oral-immune-checkpoint-inhibitor-that-exhibits-preclinical-anti-tumor-efficacy/ 2022-11-16T10:40:01+00:00 https://www.aurigene.com/wp-content/uploads/2022/11/publication1.png https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-prostate-cancer-nature-2022-434-439/ 2022-11-16T10:41:49+00:00 https://www.aurigene.com/wp-content/uploads/2022/11/publication2.png https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-prostate-cancer-nature-2022434-439/ 2022-12-08T11:39:02+00:00 https://www.aurigene.com/wp-content/uploads/2022/12/publication.png https://www.aurigene.com/publications/characterization-of-the-anti-tumor-immune-activation-potential-of-aur107-a-novel-small-molecule-p300-cbp-bromodomain-inhibitor-sitc-nov-2022/ 2023-04-27T06:05:40+00:00 https://www.aurigene.com/publications/odm-203-a-selective-inhibitor-of-fgfr-and-vegfr-shows-strong-antitumor-activity-and-induces-antitumor-immunity/ 2023-04-27T06:21:53+00:00 https://www.aurigene.com/publications/aur103-an-oral-small-molecule-cd47-antagonist-in-combination-with-azacytidine-and-bortezomib-exhibits-potent-anti-tumor-activity-in-myeloma-and-leukemia-models-in-vitro-and-in/ 2023-04-27T06:25:16+00:00 https://www.aurigene.com/publications/efficacy-and-safety-profile-of-au7r-104-a-small-molecule-targeting-cd47-sirp%ce%b1-pathway/ 2023-04-27T06:28:30+00:00 https://www.aurigene.com/publications/combination-efficacy-and-safety-profile-of-an-orally-bioavailable-small-molecule-agent-targeting-cd47-sirp%ce%b1-axis-cd47-antagonists/ 2023-04-27T06:29:23+00:00 https://www.aurigene.com/publications/targeting-cd47-sirp%ce%b1-interaction-by-novel-peptide-based-antagonists/ 2023-04-27T06:30:20+00:00 https://www.aurigene.com/publications/preclinical-in-vivo-evaluation-of-efficacy-pharmacokinetics-and-pharmacodynamics-of-novel-prmt5-inhibitors-in-multiple-tumor-models-prmt5i/ 2023-04-27T06:38:33+00:00 https://www.aurigene.com/publications/novel-inhibitors-of-protein-arginine-methyltransferase-5-prmt5-for-the-treatment-of-solid-tumors/ 2023-04-27T06:39:16+00:00 https://www.aurigene.com/publications/evaluation-of-au-18069-a-novel-small-molecule-cbp-p300-bromodomain-inhibitor-for-the-treatment-of-cancers/ 2023-04-27T06:40:27+00:00 https://www.aurigene.com/publications/evaluation-of-au-18069-a-novel-small-molecule-cbp-p300-bromodomain-inhibitor-for-the-treatment-of-cancers-2/ 2023-04-27T06:41:26+00:00 https://www.aurigene.com/publications/targeting-cancer-with-selective-cbp-p300-bromodomain-inhibitors/ 2023-04-27T06:42:07+00:00 https://www.aurigene.com/publications/oral-immune-checkpoint-antagonists-dually-targeting-tigit-and-pd-1-pathways-for-cancer-therapy/ 2023-04-27T06:44:11+00:00 https://www.aurigene.com/publications/an-orally-bioavailable-small-molecule-dual-antagonist-of-tigit-and-pd-l1-pathways-shows-immune-mediated-anti-tumor-activity/ 2023-04-27T06:44:58+00:00 https://www.aurigene.com/publications/discovery-of-orally-bioavailable-smarca2-4-dual-degraders-for-treatment-of-acute-myeloid-leukemia/ 2023-04-27T06:47:37+00:00 https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-prostate-cancer/ 2023-04-27T06:48:35+00:00 https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-human-cancers/ 2023-04-27T06:49:55+00:00 https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-prostate-cancer-2/ 2023-04-27T06:51:03+00:00 https://www.aurigene.com/publications/orally-bioavailable-smarca2-degraders-with-exceptional-selectivity-and-potency/ 2023-04-27T06:51:58+00:00 https://www.aurigene.com/publications/in-silico-designing-of-targeted-protein-degraders/ 2023-04-27T06:52:47+00:00 https://www.aurigene.com/publications/in-vivo-anti-tumor-efficacy-with-a-dual-degrader-of-smarca2-and-smarca4/ 2023-04-27T06:53:26+00:00 https://www.aurigene.com/publications/identification-of-smarca2-4-degraders-for-the-treatment-of-smarca4-mutant-and-other-cancers-smarca2-4-degraders/ 2023-04-28T06:59:17+00:00 https://www.aurigene.com/publications/orally-bioavailable-cbp-and-p300-selective-degraders-for-the-treatment-of-ar-and-er-dependent-cancers/ 2023-04-28T07:01:30+00:00 https://www.aurigene.com/publications/activation-of-targetable-inflammatory-immune-signaling-is-seen-in-myelodysplastic-syndromes-with-sf3b1-mutations/ 2023-04-28T07:12:09+00:00 https://www.aurigene.com/publications/protacs-current-trends-in-protein-degradation-by-proteolysis-targeting-chimeras/ 2023-04-28T07:13:42+00:00 https://www.aurigene.com/publications/aur103-an-oral-small-molecule-cd47-antagonist-in-combination-with-azacytidine-and-bortezomib-exhibits-potent-anti-tumor-activity-in-myeloma-and-leukemia-models-in-vitro/ 2023-04-28T07:18:07+00:00 https://www.aurigene.com/publications/evaluation-of-au-18069-a-novel-small-molecule-cbp-p300-bromodomain-inhibitor-for-the-treatment-of-cancers-3/ 2023-04-28T07:20:26+00:00 https://www.aurigene.com/publications/discovery-of-orally-bioavailable-smarca2-4-dual-degraders-for-treatment-of-acute-myeloid-leukemia-2/ 2023-04-28T07:21:00+00:00 https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-human-cancers-2/ 2023-04-28T07:21:34+00:00 https://www.aurigene.com/publications/targeting-swi-snf-atpases-in-enhancer-addicted-prostate-cancer-3/ 2023-04-28T07:22:11+00:00 https://www.aurigene.com/publications/discovery-of-map855-an-efficacious-and-selective-mek1-2-inhibitor-with-an-atp-competitive-mode-of-action/ 2023-04-28T07:22:45+00:00 https://www.aurigene.com/publications/small-molecule-agents-targeting-pd-1-checkpoint-pathway-for-cancer-immunotherapy-mechanisms-of-action-and-other-considerations-for-their-advanced-development/ 2023-04-28T07:24:21+00:00 https://www.aurigene.com/publications/design-synthesis-and-biological-evaluation-of-phenyl-thiazole-based-ar-v7-degraders/ 2023-04-28T07:25:06+00:00 https://www.aurigene.com/publications/irak4-modulators-for-treatment-of-hematologic-malignancies/ 2023-04-28T07:25:44+00:00 https://www.aurigene.com/publications/novel-potent-and-orally-bioavailable-small-molecule-cd73-inhibitors-for-cancer-immunotherapy/ 2023-04-28T07:30:13+00:00 https://www.aurigene.com/publications/evaluation-of-au-18069-a-novel-small-molecule-cbp-p300-bromodomain-inhibitor-for-the-treatment-of-cancers-4/ 2023-04-28T07:31:14+00:00 https://www.aurigene.com/publications/orally-bioavailable-smarca2-degraders-with-exceptional-selectivity-and-potency-2/ 2023-04-28T07:31:50+00:00 https://www.aurigene.com/publications/in-silico-designing-of-targeted-protein-degraders-2/ 2023-04-28T07:33:04+00:00 https://www.aurigene.com/publications/pd-1-derived-ca-170-is-an-oral-immune-checkpoint-inhibitor-that-exhibits-preclinical-anti-tumor-efficacy-2/ 2023-04-28T07:33:41+00:00 https://www.aurigene.com/publications/peptide-and-peptide-inspired-checkpoint-inhibitors-protein-fragments-to-cancer-immunotherapy/ 2023-04-28T07:34:11+00:00 https://www.aurigene.com/publications/selective-vulnerability-to-pyrimidine-starvation-in-hematologic-malignancies-revealed-by-ag-636-a-novel-clinical-stage-inhibitor-of-dihydroorotate-dehydrogenase/ 2023-04-28T07:37:21+00:00 https://www.aurigene.com/publications/discovery-of-ca-4948-an-orally-bioavailable-irak4-inhibitor-for-treatment-of-hematologic-malignancies-acs-medicinal-chemistry-letters/ 2023-04-28T07:37:54+00:00 https://www.aurigene.com/publications/potent-anti-tumor-activity-of-aur102-a-selective-covalent-inhibitor-of-cdk7/ 2023-04-28T07:38:37+00:00 https://www.aurigene.com/publications/structure-of-cyclin-dependent-kinase-2-cdk2-in-complex-with-the-specific-and-potent-inhibitor-cvt-313/ 2023-04-28T07:39:35+00:00 https://www.aurigene.com/publications/first-in-class-orally-bioavailable-bet-brd-degraders/ 2023-04-28T07:40:16+00:00 https://www.aurigene.com/publications/targeting-cancer-with-selective-cbp-p300-bromodomain-inhibitors-2/ 2023-04-28T07:40:52+00:00 https://www.aurigene.com/publications/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-aur101-an-ror%ce%b3t-inhibitor-in-normal-healthy-volunteers-2/ 2023-04-28T07:42:30+00:00 https://www.aurigene.com/publications/discovery-and-clinical-development-of-the-first-small-molecule-checkpoint-inhibitor-for-cancer-therapy-2/ 2023-04-28T07:46:03+00:00 https://www.aurigene.com/publications/antitumor-activity-of-odm-207-a-novel-bet-bromodomain-inhibitor-in-nonclinical-models-of-er-breast-cancer-as-single-agent-and-as-a-combination-treatment/ 2023-04-28T07:46:48+00:00 https://www.aurigene.com/publications/odm-203-a-selective-inhibitor-of-fgfr-and-vegfr-shows-strong-antitumor-activity-and-induces-antitumor-immunity-2/ 2023-04-28T07:48:11+00:00 https://www.aurigene.com/publications/highly-selective-peroxisome-proliferator-activated-receptor-%ce%b4-ppar%ce%b4-modulator-demonstrates-improved-safety-profile-compared-to-gw501516/ 2023-04-28T07:50:11+00:00 https://www.aurigene.com/publications/preclinical-evaluation-of-pd-and-efficacy-of-novel-potent-selective-and-orally-bioavailable-cdk12-covalent-inhibitors-in-tnbc-model-covalent-selective-cdk12i/ 2023-04-28T07:51:02+00:00 https://www.aurigene.com/publications/combination-efficacy-and-safety-profile-of-an-orally-bioavailable-small-molecule-agent-targeting-cd47-sirp%ce%b1-axis-cd47-antagonists-2/ 2023-04-28T07:52:32+00:00 https://www.aurigene.com/publications/preclinical-in-vivo-evaluation-of-efficacy-pharmacokinetics-and-pharmacodynamics-of-novel-prmt5-inhibitors-in-multiple-tumor-models-prmt5i-2/ 2023-04-28T07:53:15+00:00 https://www.aurigene.com/publications/identification-of-smarca2-4-degraders-for-the-treatment-of-smarca4-mutant-and-other-cancers-smarca2-4-degraders-2/ 2023-04-28T07:54:07+00:00 https://www.aurigene.com/publications/potent-anti-tumor-activity-correlated-with-inhibition-of-dna-damage-response-genes-with-highly-selective-and-orally-bioavailable-cdk12-covalent-inhibitors/ 2023-04-28T07:54:50+00:00 https://www.aurigene.com/publications/phase-2-trial-of-ca-170-a-novel-oral-small-molecule-dual-inhibitor-of-immune-checkpoints-vista-and-pd-1-in-patients-pts-with-advanced-solid-tumor-and-hodgkin-3/ 2023-04-28T07:56:49+00:00 https://www.aurigene.com/publications/oral-immune-checkpoint-antagonists-dually-targeting-tigit-and-pd-1-pathways-for-cancer-therapy-2/ 2023-04-28T07:57:28+00:00 https://www.aurigene.com/publications/in-vivo-anti-tumor-efficacy-with-a-dual-degrader-of-smarca2-and-smarca4-2/ 2023-04-28T07:58:09+00:00 https://www.aurigene.com/publications/phase-2-trial-of-ca-170-a-novel-oral-small-molecule-dual-inhibitor-of-immune-checkpoints-vista-and-pd-1-in-patients-pts-with-advanced-solid-tumor-and-hodgkin-4/ 2023-04-28T07:59:44+00:00 https://www.aurigene.com/publications/efficacy-and-safety-profile-of-au7r-104-a-small-molecule-targeting-cd47-sirp%ce%b1-pathway-2/ 2023-04-28T08:02:39+00:00 https://www.aurigene.com/publications/an-orally-bioavailable-small-molecule-dual-antagonist-of-tigit-and-pd-l1-pathways-shows-immune-mediated-anti-tumor-activity-2/ 2023-04-28T08:03:28+00:00 https://www.aurigene.com/publications/identification-of-a-novel-preclinical-candidate-for-cdk7-inhibition/ 2023-04-28T08:04:24+00:00 https://www.aurigene.com/publications/potent-small-molecule-compounds-that-selectively-inhibit-proliferation-of-abc-dlbcl-cell-lines/ 2023-04-28T08:05:06+00:00 https://www.aurigene.com/publications/immune-mediated-anti-tumor-activity-with-a-clinical-stage-bet-bromodomain-inhibitor-odm-207-in-pre-clinical-models/ 2023-04-28T08:05:54+00:00 https://www.aurigene.com/publications/targeting-cd47-sirp%ce%b1-interaction-by-novel-peptide-based-antagonists-2/ 2023-04-28T08:07:25+00:00 https://www.aurigene.com/publications/functional-antagonism-of-vsig8-mediated-immune-suppression-by-oral-vista-agents/ 2023-04-28T08:08:12+00:00 https://www.aurigene.com/publications/identification-of-a-novel-highly-selective-and-orally-bioavailable-preclinical-candidate-for-cdk7-covalent-inhibition/ 2023-04-28T09:15:56+00:00 https://www.aurigene.com/publications/novel-inhibitors-of-protein-arginine-methyltransferase-5-prmt5-for-the-treatment-of-solid-tumors-2/ 2023-04-28T09:16:52+00:00 https://www.aurigene.com/publications/dihydroorotate-dehydrogenase-dhodh-inhibitors-affect-atp-depletion-endogenous-ros-and-mediate-s-phase-arrest-in-breast-cancer-cells/ 2023-04-28T09:17:26+00:00 https://www.aurigene.com/publications/identification-of-novel-covalent-inhibitors-of-k-ras-g12c-that-are-efficacious-in-a-xenograft-model-of-nsclc/ 2023-04-28T09:18:05+00:00 https://www.aurigene.com/publications/potent-and-selective-inhibition-of-cdk7-by-novel-covalent-inhibitors/ 2023-04-28T09:19:31+00:00 https://www.aurigene.com/publications/efficacy-and-safety-of-highly-selective-novel-irak4-inhibitors-for-treatment-of-abc-dlbcl/ 2023-04-28T09:20:21+00:00 https://www.aurigene.com/publications/oral-immune-checkpoint-antagonists-targeting-pd-l1-vista-or-pd-l1-tim3-for-cancer-therapy/ 2023-04-28T09:23:56+00:00 https://www.aurigene.com/publications/odm-207-a-novel-bet-bromodomain-inhibitor-as-a-therapeutic-approach-for-the-treatment-of-prostate-and-breast-cancer/ 2023-04-28T09:27:06+00:00 https://www.aurigene.com/publications/odm-207-a-novel-bet-bromodomain-inhibitor-as-a-therapeutic-approach-for-the-treatment-of-patients-with-castration-resistant-prostate-cancer/ 2023-04-28T09:27:50+00:00 https://www.aurigene.com/publications/pre-clinical-efficacy-in-multiple-syngeneic-models-with-oral-immune-checkpoint-antagonists-targeting-pd-l1-and-tim-3/ 2023-04-28T09:28:28+00:00 https://www.aurigene.com/publications/potent-and-selective-inhibition-of-cdk7-by-novel-covalent-inhibitors-2/ 2023-04-28T09:28:56+00:00 https://www.aurigene.com/publications/novel-irak-4-inhibitors-exhibit-highly-potent-anti-proliferative-activity-in-dlbcl-cell-lines-with-activating-myd88-l265p-mutation-irak-4/ 2023-04-28T09:29:24+00:00 https://www.aurigene.com/publications/discovery-of-dihydro-isoxazole-derivatives-as-novel-inhibitors-of-nampt-for-the-treatment-of-multiple-myeloma-nampt/ 2023-04-28T09:30:12+00:00 https://www.aurigene.com/publications/structure-guided-discovery-of-2-aryl-pyridin-2-yl-1h-indole-derivatives-as-potent-and-selective-hepsin-inhibitors/ 2023-04-28T09:30:46+00:00 https://www.aurigene.com/publications/benzimidazole-derivatives-as-potential-dual-inhibitors-for-parp-1-and-dhodh/ 2023-04-28T09:31:09+00:00 https://www.aurigene.com/publications/deregulated-hepsin-protease-activity-confers-oncogenicity-by-concomitantly-augmenting-hgf-met-signaling-and-disrupting-epithelial-cohesion/ 2023-04-28T09:32:34+00:00 https://www.aurigene.com/publications/afn-1252-is-a-potent-inhibitor-of-enoyl-acp-reductase-from-burkholderia-pseudomallei-crystal-structure-mode-of-action-and-biological-activity/ 2023-04-28T09:33:21+00:00 https://www.aurigene.com/publications/dihydroorotate-dehydrogenase-dhodh-inhibitor-suppress-breast-cancer-cells-proliferation/ 2023-04-28T09:33:56+00:00 https://www.aurigene.com/publications/crystal-structure-of-atp-binding-subunit-of-an-abc-transporter-from-geobacillus-kaustophilus/ 2023-04-28T09:34:36+00:00 https://www.aurigene.com/publications/discovery-of-o-3-carbamimidoylphenyl-l-serine-amides-as-matriptase-inhibitors-using-a-fragment-linking-approach/ 2023-04-28T09:35:17+00:00 https://www.aurigene.com/publications/efficacy-of-selective-rar-related-orphan-receptor-gamma-ror%ce%b3-inverse-agonists-in-inflammatory-disease-models/ 2023-04-28T09:36:13+00:00 https://www.aurigene.com/publications/discovery-and-optimization-of-a-novel-series-of-irak-4-inhibitors-for-the-treatment-of-autoimmune-disorders/ 2023-04-28T09:37:16+00:00 https://www.aurigene.com/publications/identification-of-a-potent-inhibitor-of-enoyl-acp-reductase-fabi-from-burkholderia-pseudomallei-crystal-structure-mode-of-action-and-biological-activity/ 2023-04-28T09:38:40+00:00 https://www.aurigene.com/publications/3alkoxy-pyrrolo12bpyrazolines-as-selective-androgen-receptor-modulators-with-ideal-physicochemical-properties-for-transdermal-administration/ 2023-04-28T09:39:47+00:00 https://www.aurigene.com/publications/discovery-of-azetidine-based-ene-amides-as-potent-bacterial-enoyl-acp-reductase-fabi-inhibitors/ 2023-04-28T09:40:33+00:00 https://www.aurigene.com/publications/structure-guided-discovery-of-135-tri-substituted-benzenes-as-potent-selective-matriptase-inhibitors-exhibiting-in-vivo-antitumor-efficacy/ 2023-04-28T09:41:10+00:00 https://www.aurigene.com/publications/expression-of-the-fatty-acid-receptor-gpr120-in-the-gut-of-diet-induced-obese-rats-and-its-role-in-glp-1-secretion/ 2023-04-28T09:41:42+00:00 https://www.aurigene.com/publications/x-ray-structure-of-ptp1b-in-complex-with-a-new-ptp1b-inhibitor/ 2023-04-28T09:42:17+00:00 https://www.aurigene.com/publications/novel-inhibitors-of-nicotinamide-phosphoribosyltransferase-and-their-evaluation-in-combination-with-bortezomib/ 2023-04-28T09:43:25+00:00 https://www.aurigene.com/publications/identification-of-a-novel-series-of-orexin-receptor-antagonists-with-a-distinct-effect-on-sleep-architecture-for-the-treatment-of-insomnia/ 2023-04-28T09:44:05+00:00 https://www.aurigene.com/publications/equipotent-antagonism-towards-both-ligands-and-excellent-anti-tumor-efficacy-with-a-peptide-inhibitor-of-pd-1-immune-checkpoint-pathway/ 2023-04-28T09:44:44+00:00 https://www.aurigene.com/publications/discovery-of-potent-selective-retinoid-related-orphan-receptor-gamma-ror-gamma-inverse-agonists-for-the-treatment-of-th17-mediated-diseases/ 2023-04-28T09:45:16+00:00 https://www.aurigene.com/publications/equipotent-antagonism-transient-immune-activation-and-excellent-antitumor-efficacy-with-a-peptide-inhibitor-of-pd-1-immune-checkpoint-pathway/ 2023-04-28T09:45:52+00:00 https://www.aurigene.com/publications/identification-of-potent-bet-bromodomain-inhibitors-for-treatment-of-cancer/ 2023-04-28T09:46:39+00:00 https://www.aurigene.com/publications/novel-inhibitors-of-nicotinamide-phosphoribosyltransferase-nampt/ 2023-04-28T09:48:13+00:00 https://www.aurigene.com/publications/efficient-throughput-method-for-hygroscopicity-classification-of-active-and-inactive-pharmaceutical-ingredients-by-water-vapor-sorption-analysis/ 2023-04-28T09:49:21+00:00 https://www.aurigene.com/publications/discovery-of-pyridylbisoxybenzamide-derivatives-as-selective-matriptase-inhibitors/ 2023-04-28T09:50:01+00:00 https://www.aurigene.com/publications/discovery-of-7-azaindole-based-anaplastic-lymphoma-kinase-alk-inhibitors-wild-type-and-mutant-l1196m-active-compounds-with-unique-binding-mode/ 2023-04-28T09:50:32+00:00 https://www.aurigene.com/publications/design-and-synthesis-of-2-substituted-benzoxazoles-as-novel-ptp1b-inhibitors/ 2023-04-28T09:51:17+00:00 https://www.aurigene.com/publications/diphenylether-derivative-as-selective-inhibitor-of-protein-tyrosine-phosphatase-1b-ptp1b-over-t-cell-protein-tyrosine-phosphatase-tcptp-identified-through-virtual-screening/ 2023-04-28T09:52:54+00:00 https://www.aurigene.com/publications/inhibition-of-matriptase-results-in-efficacy-in-preclinical-models-of-osteoarthritis/ 2023-04-28T10:15:55+00:00 https://www.aurigene.com/publications/identification-of-pi3k-isoform-selective-inhibitors-for-treatment-of-inflammatory-indications/ 2023-04-28T10:16:37+00:00 https://www.aurigene.com/publications/demonstration-of-anti-tumor-efficacy-in-multiple-preclinical-cancer-models-using-a-novel-peptide-inhibitor-aurigene-012-of-the-pd-1-signaling-pathway/ 2023-04-28T10:17:08+00:00 https://www.aurigene.com/publications/preliminary-safety-evaluation-of-novel-small-molecule-inhibitors-of-caspase-3/ 2023-04-28T10:18:10+00:00 https://www.aurigene.com/publications/synthesis-and-biological-evaluation-of-3-4-aminophenyl-2-1h-indol-3-ylpropanamide-derivatives-as-novel-ptp1b-inhibitors/ 2023-04-28T10:18:46+00:00 https://www.aurigene.com/publications/developing-selective-inhibitors-of-ptp1b-over-tccptp/ 2023-04-28T10:19:38+00:00 https://www.aurigene.com/publications/investigation-of-orally-administered-small-molecule-inhibitors-of-caspase-3-in-murine-models-of-apoptosis/ 2023-04-28T10:20:13+00:00 https://www.aurigene.com/publications/discovery-of-indole-tetrafluoro-phenoxymethyl-ketone-based-potent-novel-small-molecule-inhibitors-of-caspase-3/ 2023-04-28T10:20:50+00:00 https://www.aurigene.com/publications/aurigene-012-as-a-novel-peptide-inhibitor-of-the-pd1-signaling-pathway-identification-of-a-preclinical-drug-candidate-for-cancer-therapy-natural-peptides-to-drugs/ 2023-04-28T10:21:30+00:00 https://www.aurigene.com/publications/demonstration-of-anti-tumor-efficacy-in-multiple-preclinical-cancer-models-using-a-novel-peptide-inhibitor-aurigene-012-of-the-pd-1-signaling-pathway-2/ 2023-04-28T10:22:19+00:00 https://www.aurigene.com/publications/synthesis-and-biological-evaluation-of-novel-oxalamido-derivatives-as-caspase-3-inhibitors/ 2023-04-28T10:22:55+00:00 https://www.aurigene.com/publications/cannabinoid-1-cb1-receptor-pharmacology-role-in-pain-and-recent-developments-in-emerging-cb1-agonists/ 2023-04-28T10:23:38+00:00 https://www.aurigene.com/publications/evaluation-of-the-effects-of-mitragyna-speciosa-alkaloid-extract-on-cytochrome-p450-enzymes-using-a-high-throughput-assay/ 2023-04-28T10:24:25+00:00 https://www.aurigene.com/publications/peptide-hormone-isoforms-n-terminally-branched-pyy3-36-isoforms-give-improved-lipid-and-fat-cell-metabolism-in-diet-induced-obese-mice/ 2023-04-28T10:26:23+00:00 https://www.aurigene.com/publications/peptide-architecture-adding-an-%ce%b1-helix-to-pyy-lysine-side-chain-provides-nanomolar-binding-and-body-weight-lowering-effects/ 2023-04-28T10:27:06+00:00 https://www.aurigene.com/publications/a-structure-based-strategy-for-new-drug-discovery/ 2023-04-28T10:27:41+00:00 https://www.aurigene.com/publications/development-of-dpp-iv-inhibitors/ 2023-04-28T10:29:01+00:00 https://www.aurigene.com/publications/rational-selection-of-structurally-diverse-natural-product-scaffolds-with-favorable-adme-properties-for-drug-discovery/ 2023-04-28T10:29:46+00:00 https://www.aurigene.com/publications/the-multiple-orthogonal-tools-approach-to-define-molecular-causation-in-the-validation-of-druggable-targets/ 2023-04-28T10:30:52+00:00 https://www.aurigene.com/publications/the-impact-of-structure-guided-drug-design-on-clinical-agents/ 2023-04-28T10:31:29+00:00 https://www.aurigene.com/publications/oral-immune-checkpoint-antagonist-dually-targeting-tigit-pd-1-pathways-for-cancer-therapy/ 2023-05-01T13:40:31+00:00 https://www.aurigene.com/publications/amino-acid-inspired-oral-immune-checkpoint-antagonists-for-cancer-therapy/ 2023-05-02T04:09:39+00:00 https://www.aurigene.com/publications/targeting-cbp-p300-inhibition-vs-degradation-for-potent-anti-tumor-efficacy-2/ 2023-05-02T07:07:49+00:00 https://www.aurigene.com/publications/characterization-of-the-anti-tumor-immune-activation-potential-of-aur107-a-novel-small-molecule-p300-cbp-bromodomain-inhibitor/ 2023-05-02T07:24:43+00:00 https://www.aurigene.com/publications/orally-bioavailable-cbp-and-p300-selective-degraders-for-the-treatment-of-ar-and-er-dependent-cancers-2/ 2023-05-02T07:25:49+00:00 https://www.aurigene.com/publications/a-highly-differentiated-pdl1-a2ar-dual-inhibitor-for-potential-use-in-cancer-therapy/ 2023-05-22T09:39:52+00:00 https://www.aurigene.com/publications/odm-203-a-selective-inhibitor-of-fgfr-and-vegfr-shows-strong-antitumor-activity-and-induces-antitumor-immunity-3/ 2023-05-22T11:28:46+00:00 https://www.aurigene.com/publications/first-in-human-fih-study-evaluating-the-safety-pharmacokinetics-pharmacodynamics-and-efficacy-of-aur-103-in-patients-with-relapsed-advanced-malignancies-bharat-1/ 2023-07-31T05:49:23+00:00 https://www.aurigene.com/publications/novel-covalent-cdk7-inhibitor-potently-induces-apoptosis-in-acute-myeloid-leukemia-and-synergizes-with-venetoclax/ 2023-08-08T03:23:09+00:00 https://www.aurigene.com/publications/generation-of-profound-anti-tumor-immunity-by-aur109-a-spectrum-selective-kinase-inhibitor-either-as-a-single-agent-or-in-combination-with-immune-checkpoint-inhibitors-2/ 2023-09-15T13:21:26+00:00 https://www.aurigene.com/publications/identification-of-paralog-selective-degraders-of-smarca2-and-smarca4-for-treatment-of-various-cancers/ 2024-04-03T03:55:09+00:00 https://www.aurigene.com/publications/discovery-of-aur-112-a-novel-malt1-protease-inhibitor-for-the-treatment-of-b-cell-lymphomas/ 2024-04-03T03:55:41+00:00 https://www.aurigene.com/publications/potent-anti-tumor-activity-of-a-selective-and-orally-bioavailable-reversible-covalent-cdk12-inhibitor/ 2024-04-03T03:56:30+00:00 https://www.aurigene.com/publications/discovery-of-potent-and-paralog-selective-protac-degraders-of-cbp-or-p300-proteins-for-the-treatment-of-various-cancers/ 2024-04-03T03:58:19+00:00 https://www.aurigene.com/publications/development-of-an-orally-bioavailable-mswi-snf-atpase-degrader-and-acquired-mechanisms-of-resistance-in-prostate-cancer/ 2024-04-03T03:59:15+00:00 https://www.aurigene.com/publications/targeting-cbp-p300-inhibition-vs-degradation-for-potent-anti-tumor-efficacy-drug-discovery-chemistry/ 2024-04-03T04:08:11+00:00 https://www.aurigene.com/publications/identification-of-paralog-selective-degraders-of-smarca2-and-smarca4-for-treatment-of-various-cancers-2/ 2024-04-03T04:09:56+00:00 https://www.aurigene.com/publications/discovery-of-potent-and-paralog-selective-protac-degraders-of-cbp-or-p300-proteins-for-the-treatment-of-various-cancers-2/ 2024-04-03T04:10:30+00:00 https://www.aurigene.com/publications/development-of-an-orally-bioavailable-mswi-snf-atpase-degrader-and-acquired-mechanisms-of-resistance-in-prostate-cancer-2/ 2024-04-03T04:11:10+00:00 https://www.aurigene.com/publications/targeting-the-swi-snf-complex-in-pou2f-pou2af-transcription-factor-driven-malignancies-2/ 2024-04-03T04:13:44+00:00 https://www.aurigene.com/publications/smarca2-4-degraders-relieve-the-differentiation-block-in-aml-via-changes-in-chromatin-looping-and-accessibility-2/ 2024-04-03T04:15:12+00:00 https://www.aurigene.com/publications/targeting-cbp-p300-inhibition-vs-degradation-for-potent-anti-tumor-efficacy-discovery-on-target-2/ 2024-04-03T05:45:16+00:00 https://www.aurigene.com/publications/targeting-cbp-p300-inhibition-vs-degradation-for-potent-anti-tumor-efficacy-discovery-on-target/ 2024-04-03T05:45:53+00:00 https://www.aurigene.com/publications/https-www-aurigene-com-wp-content-uploads-2023-09-aurigenes-aur109_ddr1-sik2-wnt-catenin-inhibitor-for-pfi2023-pdf/ 2024-04-03T05:55:02+00:00 https://www.aurigene.com/publications/a-highly-differentiated-small-molecule-immune-checkpoint-inhibitor-dually-targeting-pd-l1-and-a2ar-for-cancer-therapy/ 2024-05-20T06:38:45+00:00 https://www.aurigene.com/publications/targeting-cbm-a-tri-protein-signalling-hub-by-inhibition-of-malt1-for-the-treatment-of-b-cell-lymphomas/ 2024-05-20T06:39:53+00:00 https://www.aurigene.com/publications/targeting-the-swi-snf-complex-in-pou2f-pou2af-transcription-factor-driven-malignancies/ 2024-05-20T06:41:54+00:00 https://www.aurigene.com/publications/a-novel-ccr4-antagonist-induces-potent-anti-tumor-response-through-inhibition-of-treg-migration-into-the-tumor-microenvironment-2/ 2024-05-20T06:43:20+00:00 https://www.aurigene.com/publications/development-of-novel-anti-sirp%ce%b1-%ce%b2-dual-antibody-with-single-agent-phagocytosis-activity-2/ 2024-05-20T06:44:49+00:00 https://www.aurigene.com/publications/identification-and-characterization-of-paralogue-selective-cbp-degraders-for-potential-use-in-cancer-therapy-2/ 2024-05-20T06:46:12+00:00 https://www.aurigene.com/publications/paralogue-selective-p300-degraders-induce-synthetic-lethality-in-pre-clinical-models-of-cbp-deficient-and-p300-dependent-malignancies-2/ 2024-05-20T06:47:49+00:00 https://www.aurigene.com/publications/smarca2-4-degraders-relieve-the-differentiation-block-in-aml-via-changes-in-chromatin-looping-and-accessibility-3/ 2024-05-20T06:50:06+00:00 https://www.aurigene.com/publications/targeting-the-mswi-snf-complex-in-pou2f-pou2af-transcription-factor-driven-malignancies/ 2024-08-14T04:06:36+00:00 https://www.aurigene.com/publications/distinctive-roles-for-small-molecule-inhibitors-of-immune-checkpoint-proteins-le072/ 2024-09-02T06:15:38+00:00 https://www.aurigene.com/publications/discovery-and-development-of-pan-kras-degraders-for-cancer-therapy-discovery-on-target-september-2024/ 2024-09-24T04:49:52+00:00 https://www.aurigene.com/publications/efficacy-of-a-first-in-class-polymerase-theta-degrader-in-preclinical-cancer-models/ 2024-09-25T04:37:15+00:00 https://www.aurigene.com/publications/identification-of-first-in-class-paralog-selective-smarca4-degraders-for-treatment-of-haematological-and-prostate-malignancies/ 2025-06-05T04:51:34+00:00 https://www.aurigene.com/publications/discovery-of-highly-selective-potent-and-orally-bio-available-smarca2-degraders/ 2025-06-05T04:54:35+00:00 https://www.aurigene.com/publications/discovery-and-development-of-a-highly-cooperative-and-potent-pan-kras-degrader/ 2025-06-05T04:57:20+00:00 https://www.aurigene.com/publications/identification-of-an-orally-bio-available-smarca2-selective-degrader-for-treatment-of-smarca4-mutant-cancers/ 2025-11-19T03:17:32+00:00 https://www.aurigene.com/publications/discovery-and-development-of-a-highly-differentiated-efficacious-first-in-class-anti-sirp%ce%b1-%ce%b2-dual-antibody-with-single-agent-phagocytosis-activity/ 2025-11-19T03:18:59+00:00 https://www.aurigene.com/publications/discovery-and-preclinical-characterization-of-novel-macrocyclic-kif18a-inhibitors-for-treatment-of-chromosomally-instable-tumors/ 2025-11-19T03:20:54+00:00 https://www.aurigene.com/publications/development-of-a-differentiated-best-in-class-oral-cbl-b-inhibitor-with-robust-immune-activation-and-favourable-safety-for-cancer-immunotherapy/ 2025-11-19T03:21:40+00:00 https://www.aurigene.com/publications/novel-il-15-modules-promote-long-term-persistence-repeated-tumor-killing-and-self-sustenance-of-chimeric-antigen-receptor-natural-killer-car-nk-cells-manufactured-using-an-indigenous-platform/ 2025-12-31T09:33:07+00:00 https://www.aurigene.com/publications/discovery-and-characterization-of-once-a-month-intravenously-and-orally-bioavailable-smarca2-degraders-for-treating-smarca4-mutant-cancers/ 2026-04-17T02:45:35+00:00 https://www.aurigene.com/publications/exceptionally-selective-and-orally-bioavailable-p300-degraders-for-the-treatment-of-cbp-mutant-and-p300-dependent-cancers/ 2026-04-17T02:47:06+00:00 https://www.aurigene.com/publications/selective-degradation-of-smarca4-as-a-therapeutic-strategy-in-smarca4-driven-cancers/ 2026-04-22T03:15:44+00:00